New interesting findings for the tumor marker UBC® Rapid | IDL Biotech
IDL Biotech

CLOSE MENU

Articles

Latest News

March 2016

New interesting findings for the tumor marker UBC® Rapid

Result from a new German multicenter study

At this year’s EAU (European Association of Urology) meeting in Munich, March 11-15, a German multi-center study on UBC® Rapid was presented. Responsible for the study was Dr Thorsten Ecke, Helios Hospital, Department of Urology, Bad Sarrow. Urine samples were analyzed by UBC®Rapid POC test and evaluated quantitatively. The study showed very high sensitivity and specificity for high grade tumors generally 71/94%, and for CIS patients the sensitivity was even higher 87%.The authors concluded that UBC® Rapid should be added in the diagnostics for high risk bladder cancer and in particular for CIS patients with tumors in the bladder.

 

IDL has hired a new production manager

IDL is proud to announce that Jeanpierre Salas Montes will take over as production manager at IDL Biotech. Ola Eklund has decided to retire after more than 20 years at IDL.

Charlotte Berg leaves the position as CEO of IDL Biotech AB (publ)

IDL Biotech's CEO, Charlotte Berg, has informed the Board that, after more than ten years at the company, she wishes to resign as CEO to start another assignment in a non-competing company.

IDL Biotech

Skip this intro